An Open-Label, Phase II Study of Weekly ABI-007 as First Line Therapy for Patients With Metastatic Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 07 Jun 2016
At a glance
- Drugs Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 19 Jun 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 09 Sep 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 23 Feb 2010 Planned end date changed from 1 Mar 2011 to 1 Dec 2014 as reported by ClinicalTrials.gov.